drugset / Trial / NCT00239421

A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

NCT00239421

Phase 4 Completed 605 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the efficacy and safety of tiotropium plus formoterol in comparison to salmeterol plus fluticasone in COPD patients.

Timeline

Start
2003-11
Primary completion
2004-09
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 500 ug Inhaled
Subject Formoterol Other / unclassified 12 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled